The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: cross-sectional study

Takahisa Handa
Hokkaido Daigaku Daigakuin Igakuin

Akinobu Nakamura (akinbo@tim.hi-ho.ne.jp)
Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
https://orcid.org/0000-0002-8192-0006

Aika Miya
Hokkaido Daigaku Daigakuin Igakuin

Hiroshi Nomoto
Hokkaido Daigaku Daigakuin Igakuin

Hiraku Kameda
Hokkaido Daigaku Daigakuin Igakuin

Kyu Yong Cho
Hokkaido Daigaku Daigakuin Igakuin

So Nagai
NTT Sapporo Medical Centre

Narihito Yoshioka
NTT Sapporo Medical Centre

Hideaki Miyoshi
Hokkaido Daigaku Daigakuin Igakuin

Tatsuya Atsumi
Hokkaido Daigaku Daigakuin Igakuin

Research

Keywords: Coefficient of variation, Continuous glucose monitoring, Hypoglycemia

DOI: https://doi.org/10.21203/rs.3.rs-128672/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

This study aimed to explore predictive factors of time below target glucose range (TBR) ≥ 1% among patients’ characteristics and glycemic variability (GV) indices using continuous glucose monitoring data in elderly patients with type 2 diabetes.

Methods

We conducted a prospective observational study on 179 (71 female) Japanese outpatients with type 2 diabetes aged ≥ 65 years. The characteristics of the participants with TBR ≥ 1% were evaluated by multivariate logistic regression analysis. Receiver-operating characteristic (ROC) curve analyses of GV indices, comprising coefficient of variation (CV), standard deviation, and mean amplitude of glycemic excursions, were performed to identify the optimal index for the identification of patients with TBR ≥ 1%.

Results

In the multivariate logistic regression analysis, none of the clinical characteristics, including HbA1c and C-peptide index, were independent markers for TBR ≥ 1%, while all three GV indices showed significant associations with TBR ≥ 1%. Among the three GV indices, CV showed the best performance based on the area under the curve in the ROC curve analyses.

Conclusions

Among elderly patients with type 2 diabetes, CV reflected TBR ≥ 1% most appropriately among the GV indices examined.

Trial registration: UMIN-CTR: UMIN000029993. Registered 16 November 2017

Introduction

The number of elderly patients with diabetes increased to 111.2 million worldwide in 2019 [1], reflecting a substantial burden on the medical care system. The common features of these patients are the likelihood of having hypoglycemia associated with decreasing quality of life [2] and falls leading to bone fractures [3]. In addition, severe hypoglycemia was found to be associated with dementia [4], cardiovascular diseases and mortality risk [5] in these patients. Thus, elderly patients with diabetes require treatments that can prevent diabetic complications by stabilizing glycemic variability (GV) without hypoglycemia. Consequently, it is important to identify hypoglycemia and clarify the characteristics of these patients with hypoglycemia using real-world data.

Recently, continuous glucose monitoring (CGM) has been used worldwide for daily clinical practice. CGM traces the dynamical levels of glucose in interstitial fluid within subcutaneous fatty tissue over the whole
day and night, making it possible to estimate GV and to detect hypoglycemia and hyperglycemia. An international consensus recommended the coefficient of variation (CV) as the main measure of GV, because it can predict hypoglycemia more accurately than other GV indices including the standard deviation (SD) [6]. Stable GV was defined as CV < 36% and unstable GV defined as CV ≥ 36%, reflecting the frequency of hypoglycemia in all age groups [7]. The international consensus also recommended percentage of time below target glucose range (TBR) < 1% as an appropriate CGM-related value for prevention of hypoglycemia in elderly patients with diabetes [8].

However, there are few clinical studies on the characteristics of elderly patients with diabetes and TBR ≥ 1%. Furthermore, the relationships between TBR ≥ 1% and GV indices in CGM for elderly patients with diabetes remain to be fully characterized.

This study aimed to explore predictive factors of TBR ≥ 1% among patients’ characteristics and GV indices using continuous glucose monitoring data in elderly patients with type 2 diabetes.

**Materials And Methods**

**Study design and participants**

The present study was a secondary analysis of a previous study with a multicenter (four sites), observational, prospective, cross-sectional design that utilized CGM [9]. Briefly, patients aged ≥ 20 years were included in this study when they consented to undergo ambulatory CGM without regard to levels of HbA1c, duration of diabetes, sex, and diabetic complications. The exclusion criteria were as follows: patients with type 1 diabetes; patients who had been hospitalized within the past 3 months; patients with diabetic ketosis or in diabetic coma, with serious infection, within preoperative or postoperative periods, or with trauma during the past 6 months; and patients administrated steroid treatments, were lactating or pregnant, or had difficulty consuming a normal diet. Patients provided clinical information (age, sex, anthropometric measurements, duration of diabetes in years, treatment regimen, and medical history), fasting blood samples, and CGM data. For the present study, we extracted data for patients aged ≥ 65 years among the enrolled patients.

The study was applied for the University Hospital Medical Information Network (UMIN) Center (registration number: UMIN 000029993). The study protocol was accepted by the Institutional Review Board at Hokkaido University Hospital Clinical Research and Medical Innovation Center (017–0147). It was conducted in accordance with the Declaration of Helsinki. Signed informed consent was obtained from all the patients.

**Biochemical analyses and data collection**

Patients’ weight and height were measured using a calibrated scale. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Further information including age, sex, treatment regimen, and medical history was taken with a questionnaire administered by the
attending physicians. Blood samples were collected for this study after an overnight fast to measure the levels of HbA1c, fasting plasma glucose (FPG), C-peptide (CPR), and estimated glomerular filtration rate. The C-peptide index (CPI) was obtained by the following formula: \(100 \times \frac{\text{fasting CPR (ng/mL)}}{\text{plasma glucose (mg/dL)}}\), and applied to the reflection of endogenous insulin secretion [10].

Between 2018 and 2019, all patients went through ambulatory CGM for 14 consecutive days by means of the same technology (FreeStyle Libre Pro Sensor; Abbott Diabetes Care, Alameda, CA, USA). We analyzed the CGM data for patients with at least 4 days of recorded data available. Data for the first and last days of wearing the device were excluded from the analysis because of concerns regarding the accuracy of the CGM system during attachment and detachment [11]. Several indices for GV were calculated using GlyCulator2 software [12], as follows: CV (100 × [SD of glucose] / [mean glucose]), SD, and mean amplitude of glycemic excursions (MAGE) [13]. Moreover, we calculated three key measurements of CGM, comprising percentage of time within target glucose range (TIR; 70–180 mg/dL), percentage of time above target glucose range (TAR; >180 mg/dL), and percentage of TBR (< 70 mg/dL), in accordance with the international consensus recommendation [8].

### Statistical analysis

As described above, international consensus recommended TBR < 1% as an appropriate CGM-related value for prevention of hypoglycemia in elderly patients with diabetes [8]. Therefore, to determine the characteristics of elderly patients with diabetes who developed hypoglycemia, we assigned the patients to two subgroups: TBR ≥ 1% and TBR < 1%. For clinical factors related to TBR, comparisons between the two groups were performed by the Mann–Whitney U-test for means of continuous variables and Fisher’s exact test for proportions of categorical variables. Data are shown as mean ± standard deviation.

To analyze the characteristics of elderly patients with diabetes and TBR ≥ 1%, significant variables at value of \(P < 0.05\) in univariate analysis were examined in multivariate logistic regression analysis for each GV index. To further determine the best GV index for identifying TBR ≥ 1% in elderly patients with diabetes as well as the optimal cut-off point for each GV index corresponding to TBR ≥ 1%, receiver-operating characteristic (ROC) curve analyses were carried out for the GV indices. All tests were two-sided, and \(P < 0.05\) was taken to show statistical significance. All statistical analyses were carried out using JMP 14 software (SAS Inc., Cary, NC, USA).

### Results

Among these 311 patients, 27 were excluded since they met at least one exclusion criteria described previously [9]. Furthermore, 105 patients aged < 65 years were excluded. The remaining 179 patients (71 females) were considered eligible and included in the analyses (Fig. 1).

The 179 elderly patients with type 2 diabetes were divided into two subgroups: TBR ≥ 1% (n = 57) and TBR < 1% (n = 122). Table 1 shows the anthropometric and biochemical characteristics of the full analysis group and the two subgroups. Compared with the TBR < 1% group, the TBR ≥ 1% group had significantly
higher rate of insulin treatment and history of stroke or transient ischemic attack (TIA), and lower FPG, HbA1c, and CPI levels. For the three GV indices, CV, SD and MAGE were significantly higher in the TBR $\geq$ 1% group compared with the TBR < 1% group (Table 2). TAR in the TBR $\geq$ 1% group was significantly lower than that in the TBR < 1% group although there was no significant difference in TIR between the two groups (Table 2). There were no indications of multicollinearity between these variables (data not shown).

Multivariate logistic regression analysis showed that all the three GV indices were independent predictive markers for TBR $\geq$ 1%. Specifically, CV (odds ratio [OR]: 1.43; 95% confidence interval [CI]: 1.27–1.62), SD (OR: 1.28; 95% CI: 1.17–1.39), and MAGE (OR: 1.07; 95% CI: 1.04–1.10) were significantly associated with TBR $\geq$ 1% (Table 3). Although TAR was an independent predictive marker for TBR $\geq$ 1%, other clinical factors, including history of stroke or TIA, HbA1c, and CPI, were not independent markers.

Next, we constructed ROC curves, and calculated the areas under the ROC curve (AUCs) and the 95% CIs for all patients to assess the effects of CV, SD, and MAGE on TBR $\geq$ 1%. In the ROC curve analysis, CV had the best performance (AUC: 0.86; 95% CI: 0.79–0.91; Fig. 2) and the optimal cut-off point for CV to predict TBR $\geq$ 1% was 28.4 (sensitivity: 87.7%; specificity: 72.1%). The optimal cut-off points for SD and MAGE were 43.0 (AUC: 0.65; 95% CI: 0.55–0.74) and 113.7 (AUC: 0.66; 95% CI: 0.56–0.75), respectively (Fig. 2).

**Discussion**

In this study, we first demonstrated that the clinical characteristics of elderly patients with diabetes were not associated with TBR $\geq$ 1%. However, high GV indices contributed to TBR $\geq$ 1%. Among the three GV indices, CV was the most appropriate index for predicting TBR $\geq$ 1% in Japanese elderly outpatients with type 2 diabetes using CGM.

The strength of our study is that all patients in the analysis were aged $\geq$ 65 years, with the mean age being 73.9 years (Table 1). A previous cross-sectional study showed that low level of fasting CPR was associated with high risk of hypoglycemia in 98 outpatients with type 2 diabetes using CGM [14]. While that study focused on patients of all ages who were all treated with insulin, our study only enrolled elderly patients regardless of insulin therapy. For this reason, our results were different from ones in that study. Taken together, the findings suggest that the predictive markers for hypoglycemia in patients with diabetes differ between elderly patients and adult patients of all ages. Recently, an observation study involving CGM for 281 adult type 2 diabetes outpatients aged 40–75 years, including 181 patients aged 65–70 years, revealed that low HbA1c level and use of hypoglycemic agents related to hypoglycemia including sulfonylureas, glinides and insulin were associated with high TBR [15]. Although the subjects in that study were aged < 75 years, our study enrolled older patients (> 75 years) to provide more reflective data for real-world clinical practice. In addition, our study has the novelty of focusing on whether the clinical characteristics had associations with TBR $\geq$ 1% or < 1%, as the measure recommended by the international consensus to prevent hypoglycemia in elderly patients with diabetes. The result of our study
showed that none of the clinical characteristics of these patients had correlations with TBR ≥ 1%. Elderly patients are at high risk of hypoglycemia related to drugs because of liver or renal dysfunction [16]. Furthermore, these patients are at high risk of severe hypoglycemia because of their characteristic of being likely to experience hypoglycemia unawareness [17]. Thus, it is desirable to identify the existence of hypoglycemia by making effective use of CGM regardless of any characteristics in elderly patients with diabetes.

Our study showed significant associations between TBR ≥ 1% and GV indices. Unstable GV was found to be associated with hypoglycemia in a previous observational study that performed self-monitoring of blood glucose in 335 adult patients (254 with type 1 diabetes and 81 with type 2 diabetes in all age groups) and computed the Average Daily Risk Range, one of the indices for GV [18]. Another observational study that performed CGM in 88 patients (20 with type 1 diabetes and 68 with type 2 diabetes in all age groups) showed that age had positive correlations with SD and MAGE in patients with type 2 diabetes [19]. These findings indicate that elderly patients with diabetes are at high risk of unstable GV. Although our study only focused on elderly patients with diabetes, a significant association between TBR ≥ 1% and GV was found. Taken together, unstable GV has an association with hypoglycemia in elderly patients with diabetes as well as in patients in all age groups.

Although CV was an indirect index that can predict hypoglycemia without being influenced by hyperglycemia, both SD and MAGE had a bias toward hyperglycemia due to the fact that these markers are absolute measures [20, 21]. In addition, CV was more strongly associated with a key CGM measure of hypoglycemia than other indices such as SD and MAGE in our previous cross-sectional study in 284 Japanese patients with type 2 diabetes in all age groups [9]. Similarly, the present study showed that CV was a more accurate predictor of TBR ≥ 1% than SD and MAGE, even in elderly patients with type 2 diabetes.

Our study showed that low TAR had a significant association with TBR ≥ 1%. While few studies have investigated the relationship between TAR and TBR in patients with type 2 diabetes, one study conducted CGM in 85 children and adolescents with type 1 diabetes and showed a weak inverse correlation between TAR and TBR [22]. This finding is compatible with our results.

There are some limitations in the present study. First, factors that can minimize GV remain to be determined because this study had a relatively small sample size. To identify such factors, a larger prospective longitudinal study is needed. Second, the validity of the CGM measurement quality could be a limitation. In this regard, these inaccuracies were minimized by excluding data from the first and last days of wearing the device [23].

Conclusions

In conclusion, there were no associations between the clinical characteristics of Japanese elderly patients with type 2 diabetes and TBR ≥ 1% in a real-world clinical practice. Similar to previous studies on patients in all age groups, CV had the most significant association with hypoglycemia among the GV indices
examined. In elderly patients with diabetes, it is preferable to perform evaluations using CGM to confirm good blood glucose profiles without hypoglycemia.

**Abbreviations**

AUC, the areas under the ROC curve; BMI, body mass index; CGM, continuous glucose monitoring; CI, confidence interval; CKD, chronic kidney disease; CPI, C-peptide index; CV, coefficient of variation; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GLP-1, glucagon like peptide-1; GV, glycemic variability; HbA1c, glycated hemoglobin; MAGE, mean amplitude of glycemic excursions; QOL, quality of life; ROC, receiver operating characteristic; SD, standard deviation; SGLT2, sodium glucose cotransporter 2; TAR, time above target glucose range; TBR, time below target glucose range; TIA, transient ischemic attack; TIR, time in target glucose range

**Declarations**

**Ethics approval and consent to participate**

The study was conducted with approval from the Institutional Review Board at Hokkaido University Hospital Clinical Research and Medical Innovation Center, and registered with the University Hospital Medical Information Network (UMIN; number UMIN000029993).

**Consent for publication**

Not applicable

**Availability of data and material**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing Interests**

M.H. has received honoraria for lectures from Eli Lilly Japan K.K., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Co., Sumitomo Dainippon Pharma Co., Ltd., MSD K.K., Novo Nordisk Pharma, Nippon Boehringer Ingelheim Co., Kowa Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi and Novartis Pharma and has received research funding from Daiichi Sankyo Co., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co. Ltd., Abbott Japan Co., Mitsubishi Tanabe Pharma Co., Eli Lilly Japan K.K., Novo Nordisk Pharma, Kowa Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., and Taisho Pharmaceutical Co., Ltd. The other authors declare no conflict of interest.

**Funding**
This study did not supported by anywhere.

**Author's contributions**

T.H. and A.N. contributed to the implementation of the study, to the analysis of the results and the writing of the manuscript. S.N. and H.M. were involved in planning and supervised the study. H.N., H.K., T.H. and A.M. enrolled patients. T.H. and A.M. collected the data. H.N., H.K., K.Y., and H.M. aided in interpreting the data. K.Y., H.M., N.Y. and T.A. devised the main conceptual ideas and proof outline and critical review of the manuscript. We declare that all authors discussed the results and commented on the manuscript, and all authors approved the final manuscript.

**Acknowledgments**

The authors extend the special appreciation to the patients and staff who participated in this study. We thank Alison Sherwin, PhD, from Edanz Group (http:en-author-services.edanzediting.com/ac) for editing a draft of this manuscript. In the present study, no specific grants were obtained from funding agencies in the public, commercial, or not-for-profit sectors.

**References**

1. Pouya S, Inga P, Paraskevi S, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 107843.
2. Laiteerapong N, Karter AJ, Liu JY, et al. Correlates of Quality of Life in Older Adults With Diabetes: The Diabetes & Aging Study. Diabetes Care 2011; 34: 1749-1753.
3. Johnston SS, Conner C, Aagren M, et al. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 634-643.
4. Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013; 173: 1300-1306.
5. Zoungas S, Patel A, Chalmers J, et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med 2010; 363: 1410-1418.
6. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017; 40: 1631-1640.
7. Monnier L, Colette C, Wojtusciszyn A, et al. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care 2017; 40: 832-838.
8. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019; 42: 1593-1603.
9. Miya A, Nakamura A, Handa T, et al. Impaired insulin secretion predicting unstable glycemic variability and Time-Below-Range in type 2 diabetes regardless of HbA1c or diabetes treatment.
10. Funakoshi S, Fujimoto S, Hamasaki A, et al. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig 2011; 2: 297-303.

11. Bailey T, Bode BW, Christiansen MP, et al. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther 2015; 17: 787-794.

12. Pagacz K, Stawiski K, Szadkowska A, et al. GlyCulator2: an update on a web application for calculation of glycemic variability indices. Acta Diabetol 2018; 55: 877-880.

13. Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-655.

14. Merete MB, Gæde P, Hommel E, et al. Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes. Diabetes Metab 2020; 46: 61-65.

15. Kuroda N, Kusunoki Y, Osugi K, et al. Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study. J Diabetes Investig 2020 Jun 28. doi: 10.1111/jdi.13336. Online ahead of print.

16. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1121–1127.

17. Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes. Diabetes Care 2009; 32: 1513-1517.

18. Kovatchev BP, Otto E, Cox D, et al. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006; 29: 2433-2438.

19. Tanaka C, Saisho Y, Tanaka K, et al. Factors associated with glycemic variability in Japanese patients with diabetes. Diabetol Int 2014; 5: 36–42.

20. Kovatchev BP. Metrics for glycaemic control - from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol 2017; 13: 425-436.

21. Jin SM, Kim TH, Bae JC, et al. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. Diabetes Res Clin Pract 2014; 104: 266-272.

22. Urakami T, Yoshida K, Kuwabara R, et al. Individualization of recommendations from the international consensus on continuous glucose monitoring-derived metrics in Japanese children and adolescents with type 1 diabetes. Endocr J 2020 Jun 20. doi: 10.1507/endocrj.EJ20-0193. Online ahead of print.

23. Tsoukas M. Accuracy of FreeStyle Libre in Adults with Type 1 Diabetes: The Effect of Sensor Age. Diabetes Technol Ther 2020; 22: 203-207.
|                                  | Total patients | TBR $\geq$ 1% group | TBR < 1% group | $P$ value |
|----------------------------------|----------------|----------------------|---------------|-----------|
| $n$                              | 179            | 57                   | 122           |           |
| Age (years)                      | 73.0 (68.0, 78.0) | 74.0 (70.0, 79.0)    | 72.0 (68.0, 78.0) | 0.08      |
| Females (%)                      | 71 (39.7)      | 23 (40.4)            | 48 (39.3)     | 1.00      |
| BMI (kg/m$^2$)                   | 24.2 (22.0, 26.8) | 23.6 (21.2, 25.1)    | 24.5 (22.1, 27.1) | 0.05      |
| Diabetes duration (years)        | 16.0 (10.0, 24.0) | 19.0 (12.5, 25.0)    | 15.0 (9.0, 24.0) | 0.26      |
| Diabetes treatment               |                |                      |               |           |
| Any insulin (%)                  | 74 (41.3)      | 36 (63.2)            | 38 (31.2)     | <0.05     |
| Sulfonylureas (%)                | 52 (29.1)      | 16 (28.1)            | 36 (29.5)     | 1.00      |
| Glinides (%)                     | 27 (15.1)      | 11 (19.3)            | 16 (13.1)     | 0.37      |
| Metformin (%)                    | 96 (53.6)      | 34 (59.7)            | 62 (50.8)     | 0.33      |
| Thiazolidine (%)                 | 13 (7.3)       | 4 (7.0)              | 9 (7.4)       | 1.00      |
| $\alpha$-glucosidase inhibitors (%) | 33 (18.4)      | 9 (15.8)             | 24 (19.7)     | 0.68      |
| DPP-4 inhibitors (%)             | 135 (75.4)     | 42 (73.7)            | 93 (76.2)     | 0.71      |
| GLP-1 receptor agonists (%)      | 18 (10.1)      | 6 (10.5)             | 12 (9.8)      | 1.00      |
| SGLT2 inhibitors (%)             | 30 (16.8)      | 6 (10.5)             | 24 (19.7)     | 0.14      |
| Acute coronary syndrome (%)      | 26 (14.5)      | 11 (19.3)            | 15 (12.3)     | 0.26      |
| History of stroke or TIA (%)     | 25 (14.0)      | 13 (22.8)            | 12 (9.8)      | <0.05     |
| FPG (mg/dL)                      | 134.0 (116.0, 156.0) | 119.0 (105.0, 135.5) | 142 (123.0, 165.3) | <0.05     |
| HbA1c (%)                        | 7.1 (6.7, 7.7)  | 7.0 (6.6, 7.6)       | 7.2 (6.8, 7.8) | <0.05     |
| HbA1c (mmol/mol)                 | 54.1 (49.7, 60.7) | 53.0 (48.6, 59.6)    | 55.2 (50.8, 61.7) | <0.05     |
| CPI (ng/mL per mg/dL)            | 1.1 (0.7, 1.7)  | 1.0 (0.5, 1.5)       | 1.2 (0.9, 1.8) | <0.05     |
| eGFR (mL/min/1.73m$^2$)          | 62.8 (48.4, 70.0) | 58.0 (45.9, 68.3)    | 63.2 (50.6, 70.7) | 0.18      |
Values are expressed as median (interquartile range) or number (%) of patients in each category. The Mann–Whitney U-test or Fisher’s exact test was used for comparisons of the parameters between the TBR ≥1% group and TBR <1% group.

BMI: body mass index; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; SGLT2: sodium–glucose cotransporter 2; TIA: transient ischemic attack; FPG: fasting plasma glucose; CPI: C-peptide index; eGFR: estimated glomerular filtration rate; TBR: time below target glucose range.

Table 2

Comparisons of GV indices and CGM measurements between two groups (TBR ≥1% and <1%)

|              | Total patients | TBR ≥ 1% group | TBR < 1% group | P value |
|--------------|----------------|----------------|----------------|---------|
| CV (%)       | 27.9 (23.6, 33.8) | 36.6 (30.0, 43.2) | 26.0 (22.6, 29.0) | <0.05   |
| SD (mg/dL)   | 40.1 (30.0, 51.4) | 48.9 (35.5, 63.0) | 38.6 (32.8, 48.0) | <0.05   |
| MAGE         | 105.8 (86.5, 136.2) | 128.2 (95.0, 158.5) | 99.2 (83.5, 125.6) | <0.05   |
| TIR (%)      | 77.4 (63.7, 87.0) | 76.1 (63.0, 84.6) | 78.1 (63.8, 87.2) | 0.41    |
| TAR (%)      | 20.4 (11.4, 32.6) | 15.8 (5.7, 27.4) | 21.9 (12.4, 35.5) | <0.05   |
| TBR (%)      | 0.2 (0.0, 2.1) | 4.8 (2.2, 14.1) | 0 (0.0, 0.2) | <0.05   |

Values are expressed as median (interquartile range) in each category. The Mann–Whitney U-test was used for comparisons of the parameters between the TBR ≥1% group and TBR <1% group.

CGM: Continuous Glucose Monitoring; CV: coefficient of variation; GV: glycemic variability; SD: standard deviation; MAGE: mean amplitude of glycemic excursions; TIR: time within target glucose range; TAR: time above target glucose range; TBR: time below target glucose range.

Table 3

Clinical factors for TBR ≥1% analyzed by multivariate logistic regression analysis

CV
|                          | Odds ratio | 95% CI       | P value |
|--------------------------|------------|--------------|---------|
| Insulin treatment        | 1.68       | 0.62–4.56    | 0.31    |
| History of stroke or TIA | 1.72       | 0.45–6.63    | 0.43    |
| HbA1c                    | 1.04       | 0.41–2.62    | 0.94    |
| CPI                      | 1.13       | 0.68–1.87    | 0.65    |
| CV                       | 1.43       | 1.27–1.62    | <0.05   |
| TAR                      | 0.90       | 0.85–0.95    | <0.05   |

### SD

|                          | Odds ratio | 95% CI       | P value |
|--------------------------|------------|--------------|---------|
| Insulin treatment        | 1.99       | 0.79–5.02    | 0.15    |
| History of stroke or TIA | 1.64       | 0.47–5.77    | 0.44    |
| HbA1c                    | 0.85       | 0.37–1.91    | 0.69    |
| CPI                      | 1.08       | 0.68–1.72    | 0.73    |
| SD                       | 1.28       | 1.17–1.39    | <0.05   |
| TAR                      | 0.79       | 0.72–0.87    | <0.05   |

### MAGE

|                          | Odds ratio | 95% CI       | P value |
|--------------------------|------------|--------------|---------|
| Insulin treatment        | 2.85       | 1.16–7.01    | <0.05   |
| History of stroke or TIA | 2.36       | 0.67–8.27    | 0.18    |
| HbA1c                    | 1.01       | 0.47–2.17    | 0.98    |
| CPI                      | 0.92       | 0.59–1.43    | 0.70    |
| MAGE                     | 1.07       | 1.04–1.10    | <0.05   |
| TAR                      | 0.84       | 0.78–0.90    | <0.05   |

TIA: transient ischemic attack; CPI: C-peptide index; CV: coefficient of variation; SD: standard deviation; MAGE: mean amplitude of glycemic excursions; CI: confidence interval; TAR: time above target glucose range; TBR: time below target glucose range

**Figures**
Figure 1

Flow chart of patients during the study.
Figure 2

Comparison of AUCs for GV indices for predicting TBR $\geq 1\%$ in receiver-operating characteristic curve analyses. The Figure 2 shows the comparison of AUCs for glycemic variability indices for predicting TBR $\geq 1\%$ in receiver-operating characteristic curve analyses for CV (a), SD (b), and MAGE (c). For CV, the cutoff point was 28.4 (AUC = 0.86; 95% CI: 0.79–0.91). For SD, the cutoff point was 43.0 (AUC = 0.65; 95% CI: 0.55–0.74). For MAGE, the cutoff point was 113.7 (AUC = 0.66; 95% CI: 0.56–0.75). AUC: area under the receiver-operating characteristic curve; TBR: time below target glucose range; CV: coefficient of variation; SD: standard deviation; MAGE: mean amplitude of glycemic excursions.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- STROBEchecklist.docx